Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

ClinicalTrials.gov ID: NCT01177397

Public ClinicalTrials.gov record NCT01177397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma

Study identification

NCT ID: NCT01177397
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 226 participants

Conditions and interventions

Conditions

Interventions

CC-223 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 19, 2010
Primary completion: Nov 14, 2016
Completion: Dec 8, 2016
Last update posted: Dec 12, 2022

2010 – 2016

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
UCLA Neuro-Oncology Program	Los Angeles	California	90095	—
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center	San Francisco	California	94115	—
Moffitt Cancer Center	Tampa	Florida	33612	—
Mayo Clinic Cancer Clinical Studies Unit	Rochester	Minnesota	55905	—
Billings Clinic	Billings	Montana	59102	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
NYU Cancer Institute - Bellevue Hospital	New York	New York	10016	—
Sarah Cannon Research Institute Drug Development Unit	Nashville	Tennessee	37203	—
Mary Crowley Medical Research Center	Dallas	Texas	75201	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01177397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 12, 2022 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01177397 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →